Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL
The net effect of the breakdown of this intra-islet homeostasis results in the dysregulation of insulin secretion, leading to significant hypoglycemia ( Somatostatin receptor distribution A large number of studies have sought to characterize the expression of SSTs in human pancreatic tissues, but cataloging the differences between them is beyond the scope of this review ( Recent work from islets isolated from CHI patients undergoing pancreatectomy for focal, diffuse, or anomalous CHI ( Somatostatin receptor ligand use in congenital hyperinsulinism Somatostatin treatment was first described in a child with CHI after 80% pancreatectomy ( via a pump in a 6-month old infant with insulin excess ( Short acting SRL treatment The strategy to use octreotide subcutaneous injections administered every 4 to 8 hours ( Long acting SRL treatment Long acting SRLs have been tried in small groups of patients with reported success ( Side effects of SRL treatment Both octreotide and lanreotide possess similar SST receptor pharmacological profiles (primarily SST2 agonists) ( Supplementary Table 1 ) and are therefore expected to have a similar range of both therapeutic and adverse effects
& Lee, B
Anti-inflammatory effect TB-500 reduces the expression of the pro-inflammatory cytokines TNF- and IL-1 in several preclinical models of tissue injury
Case progress timeline 2014-2018 The patient initially presented with unexplained weight gain and excessive fatigue
